Alnylam Pharmaceuticals Inc (ALNY)
153.86
-3.44
(-2.19%)
USD |
NASDAQ |
Jun 18, 16:00
154.84
+0.98
(+0.64%)
After-Hours: 07:34
Alnylam Pharmaceuticals Accounts Receivable (Quarterly): 321.38M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 321.38M |
December 31, 2023 | 327.79M |
September 30, 2023 | 325.44M |
June 30, 2023 | 220.64M |
March 31, 2023 | 219.43M |
December 31, 2022 | 237.96M |
September 30, 2022 | 184.51M |
June 30, 2022 | 142.27M |
March 31, 2022 | 156.53M |
December 31, 2021 | 198.57M |
September 30, 2021 | 141.06M |
June 30, 2021 | 146.59M |
March 31, 2021 | 110.63M |
December 31, 2020 | 102.41M |
September 30, 2020 | 79.12M |
June 30, 2020 | 69.12M |
March 31, 2020 | 75.57M |
December 31, 2019 | 43.01M |
September 30, 2019 | 48.11M |
June 30, 2019 | 30.74M |
March 31, 2019 | 33.80M |
December 31, 2018 | 18.76M |
September 30, 2018 | 3.362M |
June 30, 2018 | 2.961M |
March 31, 2018 | 50.77M |
Date | Value |
---|---|
December 31, 2017 | 34.00M |
September 30, 2017 | 14.64M |
June 30, 2017 | 15.40M |
March 31, 2017 | 19.46M |
December 31, 2016 | 23.33M |
September 30, 2016 | 15.15M |
June 30, 2016 | 9.514M |
March 31, 2016 | 8.814M |
December 31, 2015 | 8.298M |
September 30, 2015 | 8.13M |
June 30, 2015 | 9.403M |
March 31, 2015 | 10.11M |
December 31, 2014 | 39.94M |
September 30, 2014 | 0.384M |
June 30, 2014 | 0.089M |
March 31, 2014 | 0.164M |
December 31, 2013 | 4.248M |
September 30, 2013 | 0.609M |
June 30, 2013 | 0.46M |
March 31, 2013 | 0.558M |
December 31, 2012 | 0.104M |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 | |
December 31, 2011 | 1.468M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
30.74M
Minimum
Jun 2019
327.79M
Maximum
Dec 2023
159.04M
Average
144.43M
Median
Accounts Receivable (Quarterly) Benchmarks
BridgeBio Pharma Inc | -- |
Pfizer Inc | 10.99B |
Biomarin Pharmaceutical Inc | 637.16M |
Cytokinetics Inc | 0.834M |
Ionis Pharmaceuticals Inc | -- |